ENSC VS GMVD Stock Comparison

Performance

ENSC
10/100

ENSC returned -96.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

GMVD
10/100

GMVD returned -98.88% in the last 12 months. Based on SPY's performance of -8.85%, its performance is below average giving it a score of 10 of 100.

Technicals

ENSC
25/100

ENSC receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

GMVD
21/100

GMVD receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

ENSC
33/100

ENSC has missed earnings 3 times in the last 20 quarters.

GMVD

"Earnings" not found for GMVD

Profit

ENSC
27/100

Out of the last 20 quarters, ENSC has had 8 profitable quarters and has increased their profits year over year on 2 of them.

GMVD
40/100

Out of the last 16 quarters, GMVD has had 0 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

ENSC
50/100

ENSC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

GMVD
50/100

GMVD has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Ensysce Biosciences, Inc. Common Stock Summary

Nasdaq / ENSC

Healthcare

Biotechnology

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

G Medical Innovations Holdings Ltd. Ordinary Shares Summary

Nasdaq / GMVD

Healthcare

Medical Instruments & Supplies

G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.

Power up your portfolio